SCHEMBL5376738

SCHEMBL5376738

Br[C@H]1CCCC[C@@H]1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6900438 1.00
SCHEMBL989373 1.00
SCHEMBL5376743 1.00
SCHEMBL7052054 1.00
SCHEMBL6269441 0.95 ALDH1A1 (0.36)
SCHEMBL9718773 0.95 ALDH1A1 (0.36)
SCHEMBL12079166 0.95 ALDH1A1 (0.36)
SCHEMBL5881101 0.95
SCHEMBL13891938 0.95 ALDH1A1 (0.36)
SCHEMBL10715035 0.91 ALDH1A1 (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-1261354-A None JP disclosed
WO-2024129037-A1 EFFICIENT OXIDATIVE CHLORINATION AND BROMINATION METHOD OF OLEFINS WITH SELECTFLUOR AND TBAX (CL, BR) ATATÜRK ÜNİVERSİTESİ FİKRİ MÜLKİYET HAKLARI KOORDİNATÖRLÜĞÜ DÖNER SERMAYE İŞLETMESİ (TR) 2024-06-20 WO disclosed
US-20170315079-A1 RARE EARTH METAL INCORPORATED ZEOLITE MODIFIED ELECTRODES FOR DETECTION AND QUANTIFICATION OF HEAVY METAL IONS IN AQUEOUS SOLUTION KING FAHD UNIVERSITY OF PETROLEUM AND MINERALS (SA) 2017-11-02 US disclosed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 US disclosed
US-20090306134-A1 Muscarinic receptor antagonists THERAVANCE BIOPHARMA R&D IP, LLC 2009-12-10 US disclosed
EP-1457488-B1 Intermediates for use in the preparation of urea compounds having muscarinic receptor antagonist activity THERAVANCE INC (US) 2009-08-12 EP disclosed
US-20090111737-A1 Novel antibacterial agents THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC 2009-04-30 US disclosed
US-20090111737-A1 Novel antibacterial agents THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC 2009-04-30 US disclosed
US-7456203-B2 Muscarinic receptor antagonists THERAVANCE, INC. (US) 2008-11-25 US disclosed
US-7456203-B2 Muscarinic receptor antagonists THERAVANCE, INC. (US) 2008-11-25 US disclosed
EP-1404687-A4 FLUOROUS TRIPHASE AND OTHER MULTIPHASE SYSTEMS UNIV PITTSBURGH (US) 2004-10-27 EP disclosed
US-20040087820-A1 Catalytic oxidation of C-H bonds NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-05-06 US disclosed
EP-1404687-A2 FLUOROUS TRIPHASE AND OTHER MULTIPHASE SYSTEMS UNIVERSITY OF PITTSBURGH (US) 2004-04-07 EP disclosed
US-20030125590-A1 Fluorous triphase and other multiphase systems NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-07-03 US disclosed
WO-2002100802-A2 FLUOROUS TRIPHASE AND OTHER MULTIPHASE SYSTEMS UNIVERSITY OF PITTSBURGH (US) 2002-12-19 WO disclosed
US-5407783-A Thermostability, shelf life E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-04-18 US disclosed
JP-H01261354-A PRODUCTION OF 2-CYCLOHEXEN-1-AMINE SUMITOMO CHEM CO LTD 1989-10-18 JP disclosed
US-4567195-A Azaprostacyclins, their preparation and pharmaceutical use SCHERING, AKTIENGESELLSCHAFT (DE) 1986-01-28 US disclosed
US-4446147-A Azaprostacyclins, their preparation and pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 1984-05-01 US disclosed
EP-0059158-A2 Aza prostacyclins, their preparation and therapeutic applications SCHERING AKTIENGESELLSCHAFT (DE) 1982-09-01 EP disclosed